RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation - PubMed (original) (raw)
Review
RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation
A M Schmidt et al. Semin Thromb Hemost. 2000.
Abstract
RAGE is a multiligand member of the immunoglobulin superfamily of cell surface molecules whose properties extend the paradigm of ligand-receptor interactions. The receptor recognizes families of ligands with diverse structural features, such as advanced glycation endproducts (AGEs), amyloidogenic peptides/polypeptides, amphoterins, and S100/calgranulins rather than individual species. Engagement of RAGE by its ligands upregulates the receptor and initiates a cycle of sustained cellular perturbation; increased levels of RAGE on the cell surface make it an ideal target for subsequent ligand interactions and for propagating cellular dysfunction. At this time, the only means known to break this apparently vicious cycle appears to be blocking access to RAGE or removing the ligands. Taken together, these data suggest that RAGE has the potential to function as a progression factor in a range of disorders (AGEs are relevant to diabetes and other settings of oxidant stress, amyloidogenic peptides are relevant to amyloidoses, S100/calgranulins are relevant to inflammatory disorders, etc.) in which its ligands accumulate. The chronic juxtaposition of ligand and receptor triggers sustained cellular perturbation favoring mechanisms eventuating in tissue injury rather than those that would restore homeostasis.
Similar articles
- The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
Ramasamy R, Yan SF, Schmidt AM. Ramasamy R, et al. Trends Cardiovasc Med. 2005 Oct;15(7):237-43. doi: 10.1016/j.tcm.2005.08.003. Trends Cardiovasc Med. 2005. PMID: 16226677 Review. - RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair.
Rong LL, Gooch C, Szabolcs M, Herold KC, Lalla E, Hays AP, Yan SF, Yan SS, Schmidt AM. Rong LL, et al. Restor Neurol Neurosci. 2005;23(5-6):355-65. Restor Neurol Neurosci. 2005. PMID: 16477098 Review. - RAGE in inflammation: a new therapeutic target?
Bierhaus A, Stern DM, Nawroth PP. Bierhaus A, et al. Curr Opin Investig Drugs. 2006 Nov;7(11):985-91. Curr Opin Investig Drugs. 2006. PMID: 17117586 Review. - Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM. Kim W, et al. Ann N Y Acad Sci. 2005 Jun;1043:553-61. doi: 10.1196/annals.1338.063. Ann N Y Acad Sci. 2005. PMID: 16037278 Review. - Advanced glycation end product receptor-mediated cellular dysfunction.
Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Bierhaus A, et al. Ann N Y Acad Sci. 2005 Jun;1043:676-80. doi: 10.1196/annals.1333.077. Ann N Y Acad Sci. 2005. PMID: 16037292 Review.
Cited by
- The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study.
Malmstedt J, Kärvestedt L, Swedenborg J, Brismar K. Malmstedt J, et al. Cardiovasc Diabetol. 2015 Jul 28;14:93. doi: 10.1186/s12933-015-0257-5. Cardiovasc Diabetol. 2015. PMID: 26216409 Free PMC article. - Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer.
Taneja S, Vetter SW, Leclerc E. Taneja S, et al. Int J Mol Sci. 2021 Jul 29;22(15):8153. doi: 10.3390/ijms22158153. Int J Mol Sci. 2021. PMID: 34360919 Free PMC article. Review. - Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis.
Newkirk MM, Goldbach-Mansky R, Lee J, Hoxworth J, McCoy A, Yarboro C, Klippel J, El-Gabalawy HS. Newkirk MM, et al. Arthritis Res Ther. 2003;5(2):R82-90. doi: 10.1186/ar622. Epub 2003 Jan 6. Arthritis Res Ther. 2003. PMID: 12718751 Free PMC article. - Advanced glycation end product recognition by the receptor for AGEs.
Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, Burz DS, Schmidt AM, Hoffmann R, Shekhtman A. Xue J, et al. Structure. 2011 May 11;19(5):722-32. doi: 10.1016/j.str.2011.02.013. Structure. 2011. PMID: 21565706 Free PMC article. - Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors.
Swami P, O'Connell KA, Thiyagarajan S, Crawford A, Patil P, Radhakrishnan P, Shin S, Caffrey TC, Grunkemeyer J, Neville T, Vetter SW, Hollingsworth MA, Leclerc E. Swami P, et al. Biomolecules. 2021 Apr 1;11(4):526. doi: 10.3390/biom11040526. Biomolecules. 2021. PMID: 33915939 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources